Company profile
iCell Gene Therapeutics
CAR-T cell therapy (private)
Privately held: no public share price · USA
Assets
(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | BCMA / CD19Cell therapy | Inflammatory Bowel DiseaseSystemic Lupus Erythematosus Ulcerative Colitis, Crohn's Disease | |
| Phase 1/2 | CD33Biologic (subtype unspecified) | Acute Myeloid Leukemia | |
| Phase 1 | BCMA / CD19Cell therapy | Multiple MyelomaSystemic Lupus Erythematosus | |
| Phase 1 | CD33; CLL1 (CLEC12A) | Acute Myeloid Leukemia |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.